IP Library Granted Patent US 10,717,763
Granted Patent B2
US 10,717,763 · App. 16/274,123 · Granted Jul 21, 2020

Compositions containing HC-HA/PTX3 complexes and methods of use thereof

Inventors: Scheffer Tseng (Pinecrest, FL); Hua He (Miami, FL); Sean Tighe (Tampa, FL); Suzhen Zhang (Miami, FL); Ying-Tieng Zhu (Homestead, FL)
Assignee: TISSUETECH, INC.
C07K1/36A61K38/191A61K47/55A61K47/69A61K47/6957A61L27/34A61L27/54A61L29/085A61L29/16A61L31/10A61L31/16C07K14/47C07K14/525C07K19/00A61K38/00A61L2300/236A61L2300/252A61L2300/41A61L2300/412A61L2300/426C07K14/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,717,763
App. No.
16/274,123
Granted
Jul 21, 2020
Kind
B2
Abstract

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

Claims (20)

1. A method of reducing pain in an individual in need thereof, comprising administering to an individual having a chemical burn, severe bacterial keratitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, irradiation of ocular tumors, arthritis, or bone spurs, a therapeutically effective amount of a composition comprising (i) a reconstituted HC-HA/PTX3 (rcHC-HA/PTX3) (heavy chain-hyaluronic acid/pentraxin3) complex; and (ii) a natural polymer, adjuvant, excipient, preservative, agent for delaying absorption, filler, binder, adsorbent, buffer, or combination thereof, thereby reducing pain associated with chemical burns, severe bacterial keratitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, irradiation of ocular tumors, arthritis, or bone spurs.

2. The method of claim 1 , wherein the rcHC-HA/PTX3 complex comprises hyaluronic acid (HA), heavy chain 1 (HC1) and heavy chain 2 (HC2) of inter-α-inhibitor (IαI) protein, and pentraxin 3 (PTX3).

3. The method of claim 1 , wherein the administering is to an epidermis, dermis, hypodermis, sclera, cornea, retina, choroid, vitreous, optic nerve, nerve, tendon, tissue surrounding tendon, joint, or spine.

4. The method of claim 1 , wherein the administering is by topical administration, injection, infusion, inhalation, or implantation.

5. The method of claim 4 , wherein the injection is a subconjunctival injection, intracorneal injection, intravitreal injection, intrastromal injection, intraarterial injection, intracardiac injection, intraduodenal injection, intramedullary injection, intraosseous injection, intraperitoneal injection, intrathecal injection, intravascular injection, epidural injection, parenteral injection, enteral injection, subcutaneous injection, percutaneous injection, transdermal injection, intradermal injection, or injection into a joint.

6. The method of claim 1 , wherein the composition is a solution, suspension, gel, powder, ointment, tablet, capsule, cream, lotion, paste, stick, syrup, granule, pill, aerosol, injectable depot preparation, or combinations thereof.

7. The method of claim 1 , wherein the complex further comprises a small leucine rich proteoglycan (SLRP).

8. The method of claim 1 , wherein the natural polymer comprises hyaluronic acid, collagen, fibrin, fibronectin, laminin, keratin, fibrinogen, heparan sulfate, chondroitin sulfate, or combinations thereof.

9. The method of claim 1 , wherein the excipient is a tonicity agent.

10. The method of claim 9 , wherein the tonicity agent is sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfate, or ammonium sulfate.

11. The method of claim 1 , wherein the excipient is a clarifying agent.

12. The method of claim 11 , wherein the clarifying agent is polysorbate 20, polysorbate 80, or combinations thereof.

13. The method of claim 1 , wherein the excipient is a viscosity enhancer.

14. The method of claim 13 , wherein the viscosity enhancer is carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate, or dextran.

15. The method of claim 1 , wherein the excipient is a solubilizing agent.

16. The method of claim 15 , wherein the solubilizing agent is glucan sulfate, cyclodextrin, derivatives thereof, or a combination thereof.

17. The method of claim 1 , further comprising administering to the individual an additional therapeutic agent.

18. The method of claim 1 , wherein the composition comprises liposomes, niosomes, pharmacosomes, microspheres, microparticles, or nanoparticles.

19. The method of claim 1 , wherein the rcHC-HA/PTX3 complex consists of HMW HA, HC1, HC2, and PTX3.

20. The method of claim 1 , wherein the rcHC-HA/PTX3 complex consists of HMW HA, HC1, HC2, PTX3, and TSG-6.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FUNDING IV TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0200 →
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FINANCIAL TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0165 →
CHANGE OF NAME Recorded May 22, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063713/0329 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - TERM LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 060116/0413 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - REVOLVING LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 060116/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2019
From: TSENG, SCHEFFER; HE, HUA; TIGHE, SEAN; ZHANG, SUZHEN; ZHU, YING-TIENG
To: TISSUETECH, INC.
Reel/Frame 048978/0790 →
Continuity (4)
Continuation 15214706 · Jul 20, 2016
Continuation 14414047
Provisional Application 61670571 · Jul 11, 2012
Related Publication 20190169231A1 · Jun 6, 2019
Cited By (1)
US 12,558,379